<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20151107024909N11</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-10-09</date_registration>
      <primary_sponsor>Iran University of Medical Sciences</primary_sponsor>
      <public_title>Cis atracurium and Tourniquet</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of onset, duration and recovery time of neuromuscular blockage of Cis atracurium administration before and after inflation of Tourniquet on upper limb: Randomized clinical trial.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-09-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>24</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/57526</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: For this purpose, we will use the Balanced Block Randomization method (block size=4). Random allocation software will be used for determining the sequences of blocks. In each block, there are two A for "After" and two B for "Before". For each eligible patient, the group are determined by randomized selected sequence, and after completing one block (n=4), the next  randomized selected sequence will be used to complete next block until all of the eight blocks complete, Blinding description: No information will be provided to clinical caregivers, about which group receive the drug before or after inflation of tourniquet.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Cis atracurium.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: The night before the operation, if there are conditions for inclusion in the study based on inclusion and exclusion criteria, regarding the study and actions taken in this study on the patient and its side effects and benefits are explained to the patient according to the consent form and satisfaction Is obtained. Based on the Balanced Block Randomization method, the patient is placed in one of groups A or B. In group A, up on entering the operating room, patients are non-invasively monitored for heart rate, blood pressure, and arterial blood oxygen saturation. Patients are also hydrated by a suitable peripheral vein and pre-oxygenated by a face mask. The tourniquet cuff (RS 3000 made by Ryan, CO. Iran) is closed around the arm which does not have a peripheral vein catheter and also the electrodes which detect train of four (TOF) contraction (TOF Watch SX Organon Ltd Swords, Co. Dublin Ireland) is placed in the wrist of both upper limbs over ulnar nerve and thumb to detect the contractions of adductor pollicis muscle. For sedation, patients received midazolam 0.05 milligram per kilogram of ideal body weight (mg/kg IBW) made by (EXIR, CO. Iran) and fentanyl one microgram per kilogram of ideal body weight (µg /kg IBW) made by (Caspian, CO. Iran) intravenously and after sedation of the patient, train of four (TOF) detector is calibrated. Induction of patients is started by administration of lidocaine 1/5 mg/kg IBW (made by Caspian, CO. Iran) and propofol 2 mg/kg IBW (made by Ferzenius Cabi, CO. Austria) and then Cis atracurium is administered intravenously at a dose of 0/02 mg/kg IBW, (made by Rosa Mod, CO. Iran) and the stopwatch is started immediately. When the TOF count, shows zero number of muscle contractions in one limb, this time indicates that complete block is obtained. At this time, tourniquet inflates through five seconds up to a pressure of 100 mm Hg over patient´s basic blood pressure, and the patient is intubated and the time to reach the block and the duration of the block and the recovery time in both limbs are measured separately. When the sequence of TOF remains zero, this period of time shows complete block.  The time between the appearance of the first and second contraction (TOF=1 till 2) is considered as the recovery time. After recording the above parameters, the tourniquet is deflated and the anesthesia is continued with the administration of the appropriate muscle relaxant dose. Intervention 2: Control group: In group B, up on entering the operating room, patients are non-invasively monitored for heart rate, blood pressure, and arterial blood oxygen saturation. Patients are also hydrated by a suitable peripheral vein and pre-oxygenated by a face mask. The tourniquet cuff (RS 3000 made by Ryan, CO. Iran) is closed around the arm which does not have a peripheral vein catheter and also the electrodes which detect train of four (TOF) contraction (TOF Watch SX Organon Ltd Swords, Co. Dublin Ireland) is placed in the wrist of both upper limbs over ulnar nerve and thumb to detect the contractions of adductor pollicis muscle. For sedation, patients received midazolam 0.05 milligram per kilogram of ideal body weight (mg/kg IBW) made by (EXIR, CO. Iran) and fentanyl one microgram per kilogram of ideal body weight (µg /kg IBW) made by (Caspian, CO. Iran) intravenously and after sedation of the patient, train of four (TOF) detector is calibrated. Induction of patients is started by administration of lidocaine 1/5 mg/kg IBW (made by Caspian, CO. Iran) and propofol 2 mg/kg IBW (made by Ferzenius Cabi, CO. Austria) and then tourniquet inflates through five seconds up to a pressure of 100 mm Hg over patient´s basic blood pressure and then Cis atracurium is administered intravenously at a dose of 0/02 mg/kg IBW, (made by Rosa Mod, CO. Iran) and the stopwatch is started immediately. When the TOF count, shows zero number of muscle contractions in one limb, this time indicates that complete block is obtained. At this time, the patient is intubated and the time to reach the block and the duration of the block and the recovery time in both limbs are measured separately. When the sequence of TOF remains zero, this period of time shows complete block.  The time between the appearance of the first and second contraction (TOF=1 till 2) is considered as the recovery time. After recording the above parameters, the tourniquet is deflated and the anesthesia is continued with the administration of the appropriate muscle relaxant dose.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is The decision about publication of trial will be done after end of trial and related  to its results.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Saeed aghakhani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Anesthesiology Department, Firozgar Hospital, Behafarin St. Karimkhan Av.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1593748711</zip>
        <telephone>+98 21 8894 6267</telephone>
        <email>aghakhani.said@gmail.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Faranak Rokhtabnak</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Anesthesiology Department, Firozgar Hospital, Behafarin St. Karimkhan Av.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1593748711</zip>
        <telephone>+98 21 8894 6267</telephone>
        <email>rolhtabnak.f@iums.ac.ir</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Operation is elective
Operation needs general anesthesia
Body mass index is between 18 -30
Age is between 20 - 60 years</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>History of liver disease
History of kidney disease
History of severe cardiopulmonary disease
History of  known neuromuscular disease such as: Guillain- Barre syndrome, Myasthenia gravis, Organophosphate and Anticholinesterase intoxication, multiple sclerosis disease and history of any musculoskeletal weakness in limbs
Usage of drugs such as: Aminoglycosides, Polymyxin, Lincomycin, Clindamycin, Tetracycline, Calcium, Magnesium, Lithium, Verapamil, Amlodipine, Anti epileptic drugs, Furosemide, Dantrolene, Azathioprine, Steroid and Tamoxifen
History of any vascular disease such as: Venous and arterial emboli, any impairment in circulation of limbs, Hemodialysis and history of any surgery on vessels of limbs.
Sickle cell anemia
Acidosis
Infection in limbs
Fracture in limbs
Tumor in limbs
Any increase in intracranial pressure
Addicted patient
Surgery on limbs that were examined
If neuromuscular monitoring is necessary during operation</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Devices</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: The night before the operation, if there are conditions for inclusion in the study based on inclusion and exclusion criteria, regarding the study and actions taken in this study on the patient and its side effects and benefits are explained to the patient according to the consent form and satisfaction Is obtained. Based on the Balanced Block Randomization method, the patient is placed in one of groups A or B. In group A, up on entering the operating room, patients are non-invasively monitored for heart rate, blood pressure, and arterial blood oxygen saturation. Patients are also hydrated by a suitable peripheral vein and pre-oxygenated by a face mask. The tourniquet cuff (RS 3000 made by Ryan, CO. Iran) is closed around the arm which does not have a peripheral vein catheter and also the electrodes which detect train of four (TOF) contraction (TOF Watch SX Organon Ltd Swords, Co. Dublin Ireland) is placed in the wrist of both upper limbs over ulnar nerve and thumb to detect the contractions of adductor pollicis muscle. For sedation, patients received midazolam 0.05 milligram per kilogram of ideal body weight (mg/kg IBW) made by (EXIR, CO. Iran) and fentanyl one microgram per kilogram of ideal body weight (µg /kg IBW) made by (Caspian, CO. Iran) intravenously and after sedation of the patient, train of four (TOF) detector is calibrated. Induction of patients is started by administration of lidocaine 1/5 mg/kg IBW (made by Caspian, CO. Iran) and propofol 2 mg/kg IBW (made by Ferzenius Cabi, CO. Austria) and then Cis atracurium is administered intravenously at a dose of 0/02 mg/kg IBW, (made by Rosa Mod, CO. Iran) and the stopwatch is started immediately. When the TOF count, shows zero number of muscle contractions in one limb, this time indicates that complete block is obtained. At this time, tourniquet inflates through five seconds up to a pressure of 100 mm Hg over patient´s basic blood pressure, and the patient is intubated and the time to reach the block and the duration of the block and the recovery time in both limbs are measured separately. When the sequence of TOF remains zero, this period of time shows complete block.  The time between the appearance of the first and second contraction (TOF=1 till 2) is considered as the recovery time. After recording the above parameters, the tourniquet is deflated and the anesthesia is continued with the administration of the appropriate muscle relaxant dose.</i_keyword>
      <i_keyword>Control group: In group B, up on entering the operating room, patients are non-invasively monitored for heart rate, blood pressure, and arterial blood oxygen saturation. Patients are also hydrated by a suitable peripheral vein and pre-oxygenated by a face mask. The tourniquet cuff (RS 3000 made by Ryan, CO. Iran) is closed around the arm which does not have a peripheral vein catheter and also the electrodes which detect train of four (TOF) contraction (TOF Watch SX Organon Ltd Swords, Co. Dublin Ireland) is placed in the wrist of both upper limbs over ulnar nerve and thumb to detect the contractions of adductor pollicis muscle. For sedation, patients received midazolam 0.05 milligram per kilogram of ideal body weight (mg/kg IBW) made by (EXIR, CO. Iran) and fentanyl one microgram per kilogram of ideal body weight (µg /kg IBW) made by (Caspian, CO. Iran) intravenously and after sedation of the patient, train of four (TOF) detector is calibrated. Induction of patients is started by administration of lidocaine 1/5 mg/kg IBW (made by Caspian, CO. Iran) and propofol 2 mg/kg IBW (made by Ferzenius Cabi, CO. Austria) and then tourniquet inflates through five seconds up to a pressure of 100 mm Hg over patient´s basic blood pressure and then Cis atracurium is administered intravenously at a dose of 0/02 mg/kg IBW, (made by Rosa Mod, CO. Iran) and the stopwatch is started immediately. When the TOF count, shows zero number of muscle contractions in one limb, this time indicates that complete block is obtained. At this time, the patient is intubated and the time to reach the block and the duration of the block and the recovery time in both limbs are measured separately. When the sequence of TOF remains zero, this period of time shows complete block.  The time between the appearance of the first and second contraction (TOF=1 till 2) is considered as the recovery time. After recording the above parameters, the tourniquet is deflated and the anesthesia is continued with the administration of the appropriate muscle relaxant dose.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Onset time of complete neuromuscular blockage. Timepoint: From administration of Cis atracurium until complete neuromuscular blockage. Method of measurement: With Chronometer.</prim_outcome>
      <prim_outcome>Complete neuromuscular block duration. Timepoint: The time between complete neuromuscular block until onset of recovery. Method of measurement: With Chronometer.</prim_outcome>
      <prim_outcome>The time of neuromuscular block recovery. Timepoint: The time between onset of recovery until complete recovery of neuromuscular block. Method of measurement: With Chronometer.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Iran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-02-08</approval_date>
        <contact_name>Ethics committee of Iran University of Medical Sciences</contact_name>
        <contact_address>Iran University of Medical Sciences, Hemmat Highway Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
